Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline's H5N1 vaccine could protect a vaccinated population against more than one strain, according to data from two studies.
Subscribe to our email newsletter
The in vivo data from the preclinical studies demonstrated that GSK's adjuvanted vaccine, containing the Vietnam H5N1 strain, was not only able to protect against the vaccine virus strain, but also provided 96% cross-protection against the drifted Indonesia strain of H5N1.
GSK hopes that the immune response elicited with this vaccine could help prepare or 'prime' the immune system to rapidly respond against variants of the H5N1 strain and therefore protect the vaccinated population in the event of an H5N1 human pandemic.
Jean Stephenne, president of the vaccine division of GSK, said: “I am extremely encouraged by the new trial data that has been reported today on GSK's candidate pre-pandemic influenza vaccine. The data confirm that our pre-pandemic influenza vaccine has the ability to recognize and kill an H5N1 strain that is different to the one contained in the vaccine.”